mva-muc1-il2
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2000 (NCT00004881)
Timeline
Indications
Mechanism of action
- Mucin-1Immunity, active
MUC1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva-muc1-il2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00415818 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2005 | Transgene |
| NCT00040170 | Phase 2 | May 1, 2002 | Transgene, University of Arizona, University of California, Los Angeles, University of Rochester |
| NCT00004881 | Phase 1 | Apr 1, 2000 | National Cancer Institute (NCI), University of California, Los Angeles |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Transgene | For profit | 2 | 2 | 2 | 2002 |
| University of California, Los Angeles | Academic/Hospital | 2 | 1 | 2 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2002 |
5 organizations
Page 1 / 1